Želatinske nanočestice presvučene mananom za polaganu i ciljanu isporuku didanozina: In vitro i in vivo vrednovanje by AMANDEEP KAUR et al.
Macrophages represent a key target of Human Immunodeficiency Virus (HIV) in
addition to CD4 positive lymphocyte cells (CD4+). Macrophages act as a major reservoir
for HIV because of their long-term survival after HIV infection and their ability to
spread virus to bystander CD4+ cells (1). In organs such as brain and reticuloendothelial
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Macrophages of the reticuloendothelial system and brain
act as major reservoir for HIV because of their long term
survival after HIV infection and ability to spread virus
particles to bystander CD4 positive lymphocyte cells.
The objective of the present study was to investigate
mannan-coated nanoparticles for macrophage targeting
of didanosine. Different didanosine loaded nanopartic-
les were prepared using the double desolvation techni-
que and were characterized in vitro, ex vivo and in vivo.
Results of the ex vivo cellular uptake study indicated 5-
-fold higher uptake of didanosine from the mannan-coa-
ted nanoparticles formulation (62.5  5.4%) by the mac-
rophages in comparison with didanosine solution in
phosphate buffer saline (PBS, pH 7.4) (12.1  2.3%). The
better cellular uptake from the nanoparticles formula-
tion was further confirmed by fluorescence microscopy
using hydrophilic 6-carboxyfluorescein as a marker. Re-
sults of the quantitative biodistribution study showed
1.7, 12.6 and 12.4 times higher localization of didanosine
in the spleen, lymph nodes and brain, respectively, after
administration of mannan-coated nanoparticles compa-
red to that after injection of didanosine solution in PBS
(pH 7.4). Results of the present study showed that the
mannan-coated nanoparticles targeted didanosine to the
macrophage by mannosyl receptor mediated endocytosis.
Keywords: macrophage, targeting, didanosine, anti-HIV,
mannan, receptor mediated endocytosis
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system (RES), which is the major reservoir, HIV is located primarily in macrophages. In
addition, lymph nodes play an important role in the propagation of HIV infection be-
cause replication of HIV virus at all stages of the acquired immunodeficiency syndrome
(AIDS) takes place in the lymphoid tissue macrophages. Altered cellular function in the
macrophages may contribute to the development and clinical progression of AIDS (2). In
addition, cytokine secretion may lead to a generation of secondary events, which are li-
kely to cause the washing syndrome, neurological manifestations of disease and change
in the T helper cell response from Type 1 to Type 2. In the case of AIDS, for instance, the
RES macrophage represents one of the most important therapeutic targets. This sugges-
ted the need to develop a dosage form that selectively delivers the drug to macrophages
and inhibits HIV replication.
Several reports are available regarding the use of carrier systems like liposomes (3),
microspheres (4) and nanoparticles (5) for macrophage targeting. Compared to other
carrier systems, engineered nanoparticles are known to have better accumulation in ma-
crophage rich organs, e.g., liver, spleen, and brain due to their preferential phagocytosis
(6). It is well known that brain acts as a major reservoir organ for HIV. Engineered nano-
particles have better potential to cross the blood brain barrier and deliver the drug selec-
tively to brain macrophages (7). Therefore, engineered nanoparticles represent an inter-
esting carrier system for the targeted delivery of antiviral agents to macrophages in an
attempt to reduce the required dose, minimize toxicity, minimize dose dependent side
effects, sustain the drug release and selectively deliver the drug to infected cells.
It is well known that macrophages internalize particulate carriers by the process of
endocytosis. Macrophages possess various surface receptors such as Fc, mannosyl, lectin
and galactosyl (8). These receptors help them in the process of recognition and endo-
cytosis of a particulate carrier. Due to this fact, carriers containing ligands such as man-
nosyl, immunoglobulin, fibronectin and galactosyl are better phagocytosed by macrop-
hages than carriers without such ligands (9).
In the present study, gelatin was selected as the polymer for preparing nanopartic-
les because it is biocompatible and biodegradable (10). Nanoparticles as a carrier system
have distinct advantages of better accumulation in macrophage rich organs and possess
the ability to cross the blood brain barrier easily compared to other carrier systems (7).
Some other advantages of nanoparticles include better in vivo stability, ease of steriliza-
tion, ease of scale-up and prevention of contamination with pyrogens during manufac-
turing.
Didanosine is a widely used anti-HIV drug. However, its oral therapy is associated
with poor gastrointestinal (GI) tolerability, narrow therapeutic index, several dose de-
pendent side effects, e.g., peripheral neuropathy, lactic acidosis and pancreatitis (11). In
addition, oral administration of didanosine suffers from poor GI stability at pH < 3.0,
first pass metabolism and variable absorption leading to poor bioavailability of 35–40%
(12). This problem, together with the need for frequent dosing, low plasma protein bind-
ing (< 5%), brief plasma elimination half-life (30 min to 4 h) points to the need to deve-
lop a suitable alternative dosage form of didanosine. In the present study, an attempt
has been made to formulate sustained and targeted release nanoparticles of didanosine
using gelatin as polymer and mannan-coating to further enhance its macrophage uptake
and its distribution in organs that act as major reservoirs of HIV.
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EXPERIMENTAL
Materials
Didanosine was received as a gift sample from Cipla Ltd., India. Gelatin type A
(bloom 100), mannan and 6-carboxyfluorescein (6-CF) were purchased from Sigma Che-
micals, USA. Hard paraffin, wax and soft paraffin were purchased from Loba Chemie,
India. Xylene, acetonitrile, diethyl ether and methanol were purchased from Ranbaxy Fi-
ne Chemicals Ltd., India.
Preparation of nanoparticles
Nanoparticles using type A gelatin as polymer were prepared using the double de-
solvation method described by Coester et al. (13) with slight modifications. Type A gela-
tin was dissolved in water by constant heating at 40  1 °C to prepare 0.1 to 0.8% (m/V)
solution. Acetone was added to the gelatin solution (25 mL) as a desolvating agent to
precipitate the high molecular mass (HMM) gelatin. The supernatant was discarded and
the HMM gelatin was redissolved by adding 25 mL distilled water and stirring at 600
rpm under constant heating at 40  1 °C. An aqueous solution of the drug (0.02 to 0.24%,
m/V) or fluorescence marker was added to the upper phase and the pH of the solution
was adjusted to 4.0 with 0.1 mol L–1 HCl. The gelatin was then desolvated again by
dropwise addition of acetone under constant stirring (1800 rpm) for 30 min. The formed
gelatin nanoparticles were crosslinked with aqueous glutaraldehyde solution (8%, V/V)
at room temperature for 10 min. The nanoparticles prepared were then sonicated (5 to 20
min). The particles were then purified by centrifugation at 10,000 rpm for 20 min and
the resulting nanoparticles were stored at 2–8 °C.
Mannan-coating of nanoparticles
Mannan-coating of the optimized nanoparticles formulation (N-C3) was carried out
using the incubation method (5). Coating solutions were prepared by dissolving man-
nan (1.0%, m/V) in hot water. Coating was done by depositing these coating solutions on
the surface of nanoparticles by mixing 1.0 mL of the preformed nanoparticle suspension
with mannan solution and stirring this mixture overnight at room temperature. Free
mannan was removed by passing through a Sephadex G-75 column (14  65 mm).
Nanoparticle characterization
Shape. – The morphology of plain and mannan-coated nanoparticles was determi-
ned by transmission electron microscopic studies on a Philips EM268D instrument (Phi-
lips, The Netherlands) at a voltage of 80 kV using the desired magnification. A thin film
of nanoparticle sample was mounted on a carbon-coated grid. The grid was dried in a
desiccator at room temperature (25  1 °C) before loading onto the microscope.
Size and zeta potential. – The particle size and size distribution of the nanoparticle
was determined by the laser diffraction method (Malvern, Zeta master, ZEM5002, Mal-
vern, UK). The nanoparticle suspension (1.0 mL) was dispersed in 4.0 mL water. Measu-
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rements were carried out at 25  1 °C by scattering light at 90°. The mean particle size
and size distribution were determined. The zeta potential of the formulation was deter-
mined using the same instrument.
Entrapment efficiency. – Entrapment efficiency of different batches of nanoparticles
was determined by the method proposed by Vandervoort and Ludwig (14). The amount
of didanosine entrapped was determined by incubating the nanoparticle suspension (1.0
mL) in 5.0 mL phosphate buffer saline (PBS, 7.4) for two hours at 800 rpm at 25  0.5 °C
in a shaker incubator. The amount of unbound drug was determined spectrophotometri-
cally (Beckman, DU-64OB, USA) at 250 nm in the supernatant obtained after separation
of nanoparticles by centrifugation at 13000 spm for 30 min.
Differential scanning calorimetry (DSC). – Physical mixtures of gelatin and drug and
drug-loaded nanoparticles were subjected to DSC analysis. Samples were accurately
weighed into DSC aluminum pans. The samples were then heated at a rate of 5 °C min–1
from 25 to 300 °C (Mettler, Toledo Star System, 821E, Switzerland).
In vitro drug release. – In vitro drug release from drug-loaded plain and mannan-
-coated nanoparticles was evaluated using the equilibrium dialysis technique at 37  1 °C.
Briefly, 2 mL of nanoparticle dispersion were put in the dialysis bag (Himedia, MWCO,
molecular mass cut off 12000–14000, pore size 2.4 nm) and were dialyzed against 100 mL
of PBS 7.4 at a rotation speed of 50 rpm. At predetermined time intervals, 1.0 mL sam-
ples were withdrawn from sampling port, filtered through 0.45-m membrane filter and
the drug content was determined spectrophotometrically. The receptor phase volume
was replenished with an equal volume of fresh PBS maintained at 37  1 °C.
Ex vivo cellular uptake studies. – The ex vivo cellular uptake of mannan-coated nano-
particles (N-C3-M), plain nanoparticle (N-C3) and PBS solution of the drug was carried
out by incubating 1 mL formulation with 2 mL of heparinized human blood at 37  1 °C.
After 2 h of incubation, the blood was added to agarose and fucose (2%) dispersion me-
dia and centrifuged at 10000 rpm for 10 min to separate monocytes/neutrophils and
macrophages. The smears were prepared on microscopic slides and dried. They were
then stained with Leishmann’s stain, washed with distilled water and allowed to dry
(15). The slides were then examined under an optical microscope. Shape and morpholo-
gy of monocytes and macrophages were observed and compared with the microscopic
examination of blood incubated with the drug solution in PBS under the same set of
conditions. Phagocytosis (%) was determined by counting the number of macrophages
that had undergone phagocytosis out of 100 cells observed at 100x magnification. At the
same time, 150 L of cell suspension was taken and an equal volume of 10% trichloro-
acetic acid solution in water was added and mixed for 2 min. The mixture was then cen-
trifuged at 3000 rpm for 10 min and a supernatant was filtered through a 0.45-m mem-
brane filter and the drug content was determined by the HPLC assay (16).
HPLC assay. – Didanosine in biological fluids was estimated by the HPLC method
as reported by Courtney et al. (16). Acetonitrile (5%) in 50 mmol L–1 ammonium phos-
phate buffer (pH 6.7) was used as mobile phase and was delivered at 1.0 mL min–1. The
injected fluid (20 L) was eluted in C8 column at room temperature and didanosine was
monitored at 250 nm using a UV detector (Waters, USA). The calibration curve with in a
concentration range from 0.05 to 10.0 g mL–1 was used to measure the didanosine con-
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centration. The relative standard deviation around the calibration line ranged from 1.0
to 6.0% and the squared correlation coefficient was over 0.9915.
Fluorescence microscopy. – Rats (Sprague Dawley strain), 6 to 8 weeks old, weighing
100–150 g, were divided into four groups of three rats each. First group received a sub-
cutaneous injection (s.c.) of 1.0 mL of 0.16% (m/V) solution of fluorescence marker 6-CF
in PBS (pH 7.4) in the dorsal part of hind paw. Second group received 1.0 mL of 0.16%
(m/V) solution of marker 6-CF orally. Third and fourth groups received subcutaneous in-
jection of 1.0 mL of the optimized plain nanoparticle formulation (N-C3) and mannan-
-coated nanoparticle formulation (N-C3-M) loaded with 6-CF (0.16%, m/V), respectively,
in the dorsal part of hind paw. Rats were sacrificed after 12 h of administration and se-
lected tissues (spleen, liver and lymph nodes) were excised, cut into small pieces and
fixed using the conventional method (17). Paraffin blocks were made, 5-m thick sec-
tions were cut using a microtome (Erma Optical Works, Japan) and examined under a
fluorescence microscope (Leica, DMRBE, Germany).
All investigations were performed after approval by the Institutional ethical com-
mittee and in accordance with the disciplinary principles and guidelines of CPCSEA
(Committee for the purpose of control and supervision of experiments on animals).
Biodistribution studies. – The protocol used for the biodistribution study was similar
to those described for the fluorescence microscopy study. Sprague Dawley rats (6 to 8
weeks old, weighing 100–150 g) were divided into four groups of three rats each. First
group received a subcutaneous injection of 1.0 mL of 0.16% (m/V) solution of didanosi-
ne in PBS (pH 7.4) in the dorsal part of hind paw. Second and third groups received a
subcutaneous injection of 1.0 mL of the plain nanoparticle formulation (N-C3) and man-
nan-coated nanoparticle formulation (N-C3-M), both loaded with didanosine (0.16%,
m/V), respectively, in the dorsal part of hind paw. Fourth group received 1.0 mL of
0.16% (m/V) solution of didanosine in PBS orally. The dose of didanosine selected for
animal study was 20.0 mg kg–1 as reported by Kaul et al. (18). Rats were sacrificed after
12 h of administration and blood was collected by cardiac puncture. At the same time,
selected tissues (spleen, liver, kidney, lymph nodes and brain) were excised, isolated,
dried and weighed. Blood was collected from cardiac puncture in a centrifuge tube at
predetermined time intervals and centrifuged at 2000 rpm for 10 minutes. Supernatant
was collected and acetonitrile was added to precipitate the proteins. The precipitated
proteins were settled by centrifugation at 2000 rpm for 15 min and the supernatant was
collected. One mL of collected supernatant was filtered through a 0.45-m filter into a
10-mL volumetric flask. Volume was made up with the mobile phase (5% acetonitrile in
50 mmol L–1 ammonium phosphate buffer) and the drug concentration was determined
by the HPLC assay.
Various organs (liver, spleen, kidney, lymph nodes and brain) were homogenized
after drying with 2 mL of PBS (7.4) using a tissue homogenizer. To the tissue homogena-
te, an equal volume of 10% (V/V) trichloroacetic acid (in water) was added and vortexed
for 30 s to precipitate tissue proteins. After precipitation of proteins, the drug was ex-
tracted by adding 10 mL of acetonitrile, followed by equilibration for 30 min at room
temperature (19). The tubes were then centrifuged for 30 min at 3000 rpm. After filtra-
tion through membrane filter, the filtrate was assayed for didanosine by the HPLC assay
as described earlier.
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Statistical analysis
Statistical analysis of data was performed using the analysis of variance (ANOVA).
RESULTS AND DISCUSSION
Nanoparticle formulations were prepared using the double desolvation technique
as described by Coester et al. (13) because the nanoparticles prepared by this method are
reported to be spherical and to exhibit small particle size, low polydispersity index and
high yield. pH selected for coacervation was 4.0 because of the poor stability of the drug
at pH < 3.0 (20). Stability study of the drug during nanoparticle preparation, as determi-
ned by HPLC, did not show significant degradation Initially, gelatin nanoparticles were
prepared using different drug concentrations (N-A1 to N-A5 containing 0.02 to 0.24%,
m/V, didanosine), different polymer concentrations (N-B1 to N-B4 containing 0.1 to 0.8%,
m/V, of gelatin) and using different sonication times (N-C1 to N-C4, 5 to 20 min) (Table
I). All these formulations were optimized on the basis of shape, size, entrapment effi-
ciency and in vitro drug release (Table II).
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Optimization of drug load
N-A1 0.02 0.2 5 –
N-A2 0.04 0.2 5 –
N-A3 0.08 0.2 5 –
N-A4 0.16 0.2 5 –
N-A5 0.24 0.2 5 –
Optimization of gelatin conc.
N-B1 0.16 0.1 5 –
N-B2 – 0.2 5 -
N-B3 – 0.4 5 –
N-B4 – 0.8 5 –
Optimization of sonication time
N-C1 0.16 0.8 5 –
N-C2 0.16 0.8 10 –
N-C3 0.16 0.8 15 –
N-C4 0.16 0.8 20 –
Mannan-coating
N-C3-M 0.16 0.8 15 1.0
Better uptake in the lymphatic system macrophages with the carrier system having
the size 100 to 150 nm is reported (3). Hence, to obtain nanoparticles in the desired size
range, the formulation was sonicated for 5, 10, 15 or 20 min. Dynamic light scattering re-
vealed that an increase in sonication time from 5 to 15 min led to significant decrease in
particle size from 235  10 nm to 120  12 nm for batch N-C3 (p < 0.05) (Table II). Hence,
15 min was considered as the optimum sonication time for preparation of nanoparticles
in a size range of 100–150 nm.
Mannan-coating of nanoparticles was undertaken with a view to increase their up-
take by the macrophage through receptor-mediated endocytosis (6). Optimum batch of
gelatin nanoparticles (N-C3) was coated with mannan (1.0%, m/V). Batch N-C3 was se-
lected as the optimum batch because it exhibited high entrapment efficiency (71.2 
3.5%), sustained release characteristic (58.8  2.9% after 24 h) and desired particle size
(120  12 nm). The coating of nanoparticles was confirmed by visualizing the nanopar-
ticles using transmission electron microscopy (Fig. 1) as well as by measuring the zeta
potential and particle size of coated formulation (Table III). Nanoparticles were found to
be spherical in shape and exhibited a significantly thick and smooth surface after subse-
quent coating with mannan and a significant increase (p < 0.05) in the size of the partic-
les from 120  12 nm to 140  19 nm (batch N-C3-M).
Figs. 2a-b show the DSC profiles of the physical admixture of didanosine and gela-
tin and gelatin nanoparticles. DSC thermogram of the physical admixture showed two
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(%) after 24 h
N-A1 Aggregate 68.4  1.4 210  12 49.0  3.1
N-A2 Aggregate 68.6  2.2 213  10 56.5  3.5
N-A3 Aggregate 70.2  2.3 211  13 61.9  3.7




69.2  2.4 215  10 86.9  4.5
N-B1 Aggregate 64.3  2.3 214  15 75.0  3.1
N-B2 Aggregate 72.4  2.0 218  15 69.0  2.3
N-B3 Aggregate 71.5  2.3 228  14 63.9  3.7
N-B4 Aggregate with smooth surface 70.8  2.5 235  10 61.9  2.7
N-C1 Aggregate 70.7  3.7 235  10 63.0  4.8








72.5  2.1 94  10 57.7  3.2
a Data are represented as mean  SD, n = 3.
b Optimized formulation.
endothermic peaks at 102.5 °C and 182.0 °C. Endothermic peak at 182 °C represents the
didanosine melting point near 180 °C and another peak near 100 °C is from gelatin (21).
The results obtained are in good agreement with those reported by Sanchez-Lafuente et
al. (22). They also found the endothermic peak of didanosine at around 180 °C. In con-
trast, the profile of the lyophilized powder of gelatin nanoparticles showed a single peak
around 200 °C (Fig. 2b) suggesting the occurrence of unique molecular interactions in
these nanoparticles. Taken together, these DSC profiles of gelatin nanoparticles demon-
strate that the gelatin nanoparticles, which were engineered from the desolvation pro-
cess comprising gelatin and didanosine, were not a simple physical admixture of the
two components. Cui et al. (5) also found that cationic gelatin nanoparticles consisting of
emulsifying wax and cetyl trimethyl ammonium bromide (CTAB) showed single peak in
the thermogram but when tested in physical admixture, different peaks appeared for
each component in the thermogram.
Fig. 3 compares the in vitro drug release profile of didanosine from mannan-coated
nanoparticles, plain nanoparticles and drug suspension. Drug was released from plain
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Fig. 1. Transmission electron microscopy photomicrograph of: a) plain nanoparticles (N-C3) and
mannan-coated nanoparticles formulation (N-C3-M) (both 15000x magnification). Error bar = 50 nm.






Particle size (nm) 120  12 140  19
Entrapment efficiency (%) 71.2  3.5 79.5  4.7
Zeta potential (z, mV) 18.6  2.1 7.2  1.8
Surface morphology Smooth Perfectly smooth
Drug release after 24 h (%) 58.8  2.9 42.5  1.7
a Data are represented as mean  SD, n = 3.
nanoparticles completely within 2 h (98.8  4.5%) compared to the gelatin nanoparticles
(N-C3), which showed only 58.8  2.9% drug release over 24 h. Coating of nanoparticles
with mannan further retarded the drug release (42.5  1.7% over 24 h). The concentra-
tion of gelatin employed for the preparation of nanoparticles had a significant effect on
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Fig. 2. DSC thermogram of: a)
physical admixture of didanosine

































ved drug (mean  SD,
n = 3).
the release rate. Increasing the gelatin concentration from 0.1 to 0.8%, m/V, significantly
(p < 0.05) decreased the release rate from 75.0  3.1% (N-B1) to 61.9  2.7% (N-B4) over
24 h. This may be due to the increase in the diffusion bilayer size as a result of the in-
crease in the concentration of gelatin, which sustained the release of didanosine from the
nanoparticles.
Table IV shows the morphological characteristics of Leishmann’s stained macropha-
ges after incubation with PBS (pH 7.4) solution of didanosine, didanosine-loaded plain
and mannan-coated nanoparticles. Microscopic visualization of the macrophages incu-
bated with mannan-coated optimized nanoparticle formulation showed a prominent ef-
fect on the morphology of macrophages (Table IV). After incubation with mannan-coa-
ted nanoparticles, these cells became swollen due to the uptake of nanoparticles and the
macrophage nucleus was observed to be nearly separated from the remaining cellular
contents. Further, complete lysis of macrophage membrane was evident with some of
the cells. However, after incubation with the drug solution, the effect on cell nucleus was
not prominent. Plain nanoparticles show effects similar to mannan-coated nanoparticles
but to a lesser extent. Coating of nanoparticles with mannan further increased the cellu-
lar uptake of nanoparticles (N-C3-M) as evident by higher staining intensity and com-
plete lysis within 2 h of incubation. The results of phagocytosis measurement also dis-
played a greater uptake of nanoparticle formulations compared to the drug solution.
Mannan-coated nanoparticles showed 88.7  6.2% phagocytosis (N-C3-M) after 2 h of in-
cubation, whereas plain nanoparticles (N-C3) and drug solution showed only 51.2  4.6
and 21.7  2.8%, respectively (Table IV).
The better cellular uptake of mannan-coated nanoparticles might be due to the pres-
ence of mannosyl receptor predominantly on the macrophage cell surface, which is used
by the cells for endocytosis and phagocytosis (5, 23). Mannosyl receptor recognizes man-
nan on cell walls of the infectious agent in the body (24). Upon binding, there is aggrega-
tion and receptor mediated endocytosis. This causes mannan-coated nanoparticles to be
phagocytized by the macrophage at a faster rate. The quantitative cellular uptake mea-
surement studies showed after 2 h of incubation five times higher uptake of didanosine
from mannan-coated nanoparticles (62.5  5.4%) and its 3 times higher uptake from
plain nanoparticles (37.2  4.1%) compared to drug solution (12.1  2.3%). Results of the
cellular uptake study were well correlated with those reported by Cui et al. (5) for the
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Adsorption + + +++
Uptake + + +++
Swelling – ++ +++
Lysis – ++ +++
Phagocytosis (%) 21.7  2.8 51.2  4.6 88.7  6.2
— – none; + – slight; ++ – moderate; +++ – good
uptake of mannan-coated gelatin nanoparticles in a mannose receptor positive (MR+)
mouse macrophage cell line.
The better cellular uptake of the nanoparticle formulation was further confirmed by
fluorescence microscopy. Marker selected for the present study was 6-CF because it has
a similar hydrophilic nature to didanosine (17). Fluorescence photomicrographs (not
shown) reveal better qualitative uptake and localization of fluorescence marker loaded
plain nanoparticles and mannan-coated nanoparticles in brain, spleen and lymph nodes
as compared to its solution. This supports the results of the ex vivo cellular uptake study.
Significantly higher concentration of the fluorescence marker, shown by higher fluores-
cence intensity, was observed after 12 h of administration in brain, spleen and lymph no-
des. No fluorescent signal was observed in the control group and a relatively weak sig-
nal was observed in case of animals treated with marker-loaded plain nanoparticles.
Biodistribution pattern of the free drug, plain and mannan-coated nanoparticles in-
to different organs was measured and the results are shown in Fig. 4. The organ distribu-
tion pattern, plasma concentration of didanosine in case of different formulations and
free drug indicate the superiority of the nanoparticulate system in increasing the accu-
mulation of didanosine in various target organs, specially in spleen, lymph nodes and
brain and its lowering in lung and kidney. Mannan-coated nanoparticles showed 12-fold
higher lymphatic distribution of the drug in comparison with drug solution in PBS. The
reason for better lymphatic uptake of mannan-coated nanoparticles is their preferential
phagocytosis by macrophages and localization in lymph nodes. After the s.c. injection of
nanoparticles into the dorsal side of the the foot, nanoparticles are efficiently absorbed
via lymphatic capillaries and localized in the lymph nodes. It has been suggested that
phagocytosis by macrophages is one of the major mechanisms of uptake of colloidal par-
ticles in lymph nodes (25).
Conventional formulations like tablets, capsules and suspensions are not able to de-
liver the drug to brain due to the nature of the blood-brain barrier (BBB). Fig. 4 compa-
res the brain concentration of didanosine after its administration in the form of drug so-
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Fig. 4. Tissue distribu-
tion of didanosine (after




particles (N-C3) and drug
solution (mean  SD, n =
3).
lution, plain nanoparticles and mannan-coated nanoparticles. The results showed 12.4-
and 6.0- fold higher accumulation of didanosine in brain when administered through
mannan-coated nanoparticles and plain nanoparticles compared to drug solution. This
was due to the presence of mannosyl receptors on macrophage cells of the brain mono-
nuclear phagocytic system as well as the inherent ability of nanoparticles to cross the
BBB by opening the tight junction between endothelial cells. This would lead to increa-
sed retention of nanoparticles in the brain capillaries combined with absorption to capil-
lary walls by receptor mediated endocytosis (6, 7). Didanosine is a hydrophilic drug and
its ability to cross the BBB is very low (11); however, mannan-coated nanoparticles rep-
resent a better approach for enhanced delivery of didanosine to brain.
The reason for better accumulation of mannan-coated gelatin nanoparticles is their
preferential macrophage uptake by RES organs, lymph nodes and brain. After adminis-
tration, nanoparticles are selectively taken up by the macrophage rich organs by recep-
tor-mediated endocytosis due to the presence of mannosyl receptor on the cell surface.
After reaching inside the cell, these nanoparticles are degraded by lysosomes and en-
trapped didanosine is released. This released didanosine will be selectively delivered to
HIV, which mainly resides in the macrophage and prevent its replication. The main rate
limiting step in this process is the stable adsorption of nanoparticles on the cell surface
(8, 9). Due to the presence of mannosyl receptor on the macrophage cell surface, these
mannan-coated nanoparticles have a high probability of stable absorption on cell surface
followed by endocytosis, as evident from the ex vivo cellular uptake study. In contrast,
free didanosine in solution is very poorly adsorbed on macrophage surface, which re-
sults in a smaller amount of drug reaching the internal compartment of macrophages.
CONCLUSIONS
Administration of mannan-coated gelatin nanoparticles resulted in a significantly
higher concentration of didanosine in spleen, lymph nodes and brain. These nanopartic-
les sustained the release of didanosine and may be used to reduce the frequency of ad-
ministration and dose-dependent side-effects, reducing the chances of dose dumping
and increasing the patient compliance.
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S A @ E T A K
@elatinske nano~estice oblo`ene mananom za polaganu i ciljanu
isporuku didanozina: In vitro i in vivo vrednovanje
AMANDEEP KAUR, SUBHEET JAIN i ASHOK K. TIWARY
Makrofagi retikuloendotelnog sustava i mozak djeluju kao glavni rezervoari za HIV
zbog njihovog dugoro~nog pre`ivljavanja nakon infekcije HIV-om i sposobnosti da usmje-
re virusne ~estice u CD4 pozitivne limfocite. Cilj rada bio je ispitati nano~estice oblo`ene
mananom za ciljanu isporuku didanozina u makrofage. Koriste}i metodu dvostruke de-
solvatacije pripravljene su razli~ite nano~estice s didanozinom te su zatim karakterizira-
ne in vitro, ex vivo i in vivo. Rezultati ex vivo ispitivanja ukazuju da je unos didanozina u
makrofage 5 puta ve}i iz nano~estica oblo`enih mananom (62,5  5,4%) u usporedbi s
otopinom didanozina u fosfatnom puferu (PBS, pH 7,4) (12,1  2,3%). Bolji celularni unos
iz nano~estica potvr|en je fluorescentnom mikroskopijom koriste}i hidrofilni 6-kar-
boksifluorescein kao marker. Rezultati kvantitativne biodistribucije pokazuju da je loka-
lizacija didanozina u slezeni, limfnim ~vorovima i mozgu 1,7, 12,6, odnosno 12,4 puta
ve}a nakon primjene nano~estica oblo`enih mananom nego nakon primjene otopine di-
danozina u PBS-u (pH 7,4). Nano~estice s mananom usmjeravaju didanozin u makrofa-
ge procesom endocitoze u kojoj posreduju receptori za manozu.
Klju~ne rije~i: makrofag, ciljana terapija, didanozin, anti-HIV, manan, endocitoza posredovana re-
ceptorima
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